At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Blood

Volumn 130, Issue 17, 2017, Pages 1946-1948

  Fitzhugh, Courtney D ^a,b   Cordes, Stefan ^a   Taylor, Tiffani ^b   Coles, Wynona ^b   Roskom, Katherine ^a   Link, Mary ^b   Hsieh, Matthew M ^b   Tisdale, John F ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HEMOGLOBIN S;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CLINICAL TRIAL; DONOR MYELOID CHIMERISM; ENGRAFTMENT; ERYTHROCYTE; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PATIENT MONITORING; PRIORITY JOURNAL; RECIPIENT; SICKLE CELL ANEMIA; SURVIVAL TIME; YOUNG ADULT; ALLOTRANSPLANTATION; ANEMIA, SICKLE CELL; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HOMOZYGOTE; METABOLISM; PATHOLOGY; PHENOTYPE;

ADULT; ANEMIA, SICKLE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN, SICKLE; HOMOZYGOTE; HUMANS; MYELOID CELLS; PHENOTYPE; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 85032461067     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-772392     Document Type: Article

References (19)

1. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014; 312(1):48-56.
2. Andreani M, Testi M, Gaziev J, et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica. 2011;96(1): 128-133.
3. Walters MC, Patience M, Leisenring W, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665-673.
4. Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016; 22(3):441-448.
5. King AA, Kamani N, Bunin N, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015; 90(12):1093-1098.
6. Kean LS, Manci EA, Perry J, et al. Chimerism and cure: Hematologic and pathologic correction of murine sickle cell disease. Blood. 2003;102(13): 4582-4593.
7. Felfly H, Trudel M. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions. Br J Haematol. 2010;148(4):646-658.
8. Iannone R, Luznik L, Engstrom LW, et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood. 2001;97(12):3960-3965.
9. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLAhaploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-4291.
10. Hsieh MM, Wu CJ, Tisdale JF. In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011;96(1):13-15.
11. Wu CJ, Hochberg EP, Rogers SA, et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003;31(10): 924-933.
12. Fitzhugh CD, Hsieh MM, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical peripheral blood stem cell transplantation. Blood Adv. 2017;1(11):652-661.
13. Roberts C, Kean L, Archer D, Balkan C, Hsu LL. Murine and math models for the level of stable mixed chimerism to cure beta-thalassemia by nonmyeloablative bone marrow transplantation. Ann N Y Acad Sci. 2005;1054:423-428.
14. Eadie GS, Brown IW Jr. Red blood cell survival studies. Blood. 1953;8(12):1110-1136.
15. Korell J, Coulter CV, Duffull SB. A statistical model for red blood cell survival. J Theor Biol. 2011;268(1):39-49.
16. Shemin D, Rittenberg D. The life span of the human red blood cell. J Biol Chem. 1946;166(2): 627-636.
17. Lindsell CJ, Franco RS, Smith EP, Joiner CH, Cohen RM. A method for the continuous calculation of the age of labeled red blood cells. Am J Hematol. 2008;83(6):454-457.
18. Altrock PM, Brendel C, Renella R, Orkin SH, Williams DA, Michor F. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016;91(9):931-937.
19. Weinstein IM, Spurling CL, Klein H, Necheles TF. Radioactive sodium chromate for the study of survival of red blood cells. III. The abnormal hemoglobin syndromes. Blood. 1954;9(12): 1155-1164.